Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell

MT Newswires Live07-08

Seres Therapeutics (MCRB) said Wednesday that top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.

The primary endpoint was defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy, such as a corticosteroid and/or a biologic immunomodulator drug.

Inhibitor-related enterocolitis, or irEC, is a frequent side effect of immune checkpoint inhibitors that often causes patients to halt cancer treatment.

"Patients receiving ICI treatment who develop irEC face significant challenges, as current management often necessitates interruption or discontinuation of checkpoint inhibitor therapy and treatment with systemic immunosuppressives, which are associated with clinically significant side effects," Principal Investigator David Faleck said in a statement.

Shares of Seres Therapeutics were up more than 6% pre-bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649699345?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649699345","market":"nz","top_or_hot":-1,"title":"Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (MCRB) said Wednesday that top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.</p><p>The primary endpoint was defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy, such as a corticosteroid and/or a biologic immunomodulator drug.</p><p>Inhibitor-related enterocolitis, or irEC, is a frequent side effect of immune checkpoint inhibitors that often causes patients to halt cancer treatment.</p><p>\"Patients receiving ICI treatment who develop irEC face significant challenges, as current management often necessitates interruption or discontinuation of checkpoint inhibitor therapy and treatment with systemic immunosuppressives, which are associated with clinically significant side effects,\" Principal Investigator David Faleck said in a statement.</p><p>Shares of Seres Therapeutics were up more than 6% pre-bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-08 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (MCRB) said Wednesday that top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.</p><p>The primary endpoint was defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy, such as a corticosteroid and/or a biologic immunomodulator drug.</p><p>Inhibitor-related enterocolitis, or irEC, is a frequent side effect of immune checkpoint inhibitors that often causes patients to halt cancer treatment.</p><p>\"Patients receiving ICI treatment who develop irEC face significant challenges, as current management often necessitates interruption or discontinuation of checkpoint inhibitor therapy and treatment with systemic immunosuppressives, which are associated with clinically significant side effects,\" Principal Investigator David Faleck said in a statement.</p><p>Shares of Seres Therapeutics were up more than 6% pre-bell.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SER","symbol_name":"Serina Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649699345","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649699345","pubTimestamp":1783511748,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Seres Therapeutics  said Wednesday that top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.The primary endpoint was defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy, such as a corticosteroid and/or a biologic immunomodulator drug.Inhibitor-related enterocolitis, or irEC, is a frequent side effect of immune checkpoint inhibitors that often causes patients to halt cancer treatment.\"Patients receiving ICI treatment who develop irEC face significant challenges, as current management often necessitates interruption or discontinuation of checkpoint inhibitor therapy and treatment with systemic immunosuppressives, which are associated with clinically significant side effects,\" Principal Investigator David Faleck said in a statement.Shares of Seres Therapeutics were up more than 6% pre-bell.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SER":"Serina Therapeutics, Inc.","BK4139":"生物科技","MCRB":"Seres Therapeutics, Inc."},"translate_title":"Seres Therapeutics的SER-155 1期试验达到主要终点；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SER":1.5,"MCRB":1.5},"content_text":"Seres Therapeutics (MCRB) said Wednesday that top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.The primary endpoint was defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy, such as a corticosteroid and/or a biologic immunomodulator drug.Inhibitor-related enterocolitis, or irEC, is a frequent side effect of immune checkpoint inhibitors that often causes patients to halt cancer treatment.\"Patients receiving ICI treatment who develop irEC face significant challenges, as current management often necessitates interruption or discontinuation of checkpoint inhibitor therapy and treatment with systemic immunosuppressives, which are associated with clinically significant side effects,\" Principal Investigator David Faleck said in a statement.Shares of Seres Therapeutics were up more than 6% pre-bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649699345","isCrawlerRequest":true}